Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.

Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top benefits for prostate cancer patients and why Cesium-131 is his exclusive isotope of choice for low dose rate brachytherapy.

For Dr. Prestidge, it comes down to the biological effectiveness dose of delivering radiation internally versus external beam delivery, the convenience of one procedure versus 45 EBRT visits (typical for prostate cancer treatment) and rapid resolution of side effects.

Watch our quick-hitting interview with Dr. Prestidge from ABS 2018.

 

 

Among his many distinctions including 12 years of service as an active duty U.S. Air Force physician and consultant to the Surgeon General, Dr. Prestidge served the recent President and Chairman of the American Brachytherapy Society and is a member of both the American College of Radiation Oncology and American Society of Clinical Oncology.

Are you ready to put Cesium-131s similar energy and shorter half-life compared to Iodine-125, along with more rapid resolution of side effects, to work for your prostate cancer patients? Contact customerservice@isoray.com to arrange a call or meeting.

You can also follow Isoray on LinkedIn, Twitter and Facebook.

My Question is Why?

My Question is Why?

By Dr. Ronald M. BenoitDepartment of Urology, University of Pittsburgh School of Medicine Why would a clinician be hesitant to use Cesium-131 to treat prostate cancer? I would venture to say the likely answer is the data that speaks to its benefits has not yet...

read more
Take Time to Think

Take Time to Think

By Dr. Bernard W. TaylorTexas Oncology - Longview Cancer Center The American Cancer Society’s 2022 Cancer Facts and Figures report estimates that nearly 270,000 men will be diagnosed with prostate cancer this year. This represents nearly 50% more than the number of...

read more
Looking Ahead

Looking Ahead

By CEO Lori Woods This is my first blog post, and it comes during a year that has changed how we communicate, how we work, and virtually every aspect of our lives. COVID-19 has challenged us and changed us. We hope for better days ahead even as we face the reality of...

read more